A detailed history of Covenant Partners, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Covenant Partners, LLC holds 9,313 shares of ABBV stock, worth $1.65 Million. This represents 0.55% of its overall portfolio holdings.

Number of Shares
9,313
Previous 9,178 1.47%
Holding current value
$1.65 Million
Previous $1.57 Million 16.84%
% of portfolio
0.55%
Previous 0.49%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

BUY
$163.84 - $199.33 $22,118 - $26,909
135 Added 1.47%
9,313 $1.84 Million
Q3 2022

Nov 10, 2022

SELL
$134.21 - $153.93 $236,343 - $271,070
-1,761 Reduced 16.1%
9,178 $1.23 Million
Q1 2022

May 16, 2022

SELL
$131.98 - $163.75 $7,126 - $8,842
-54 Reduced 0.49%
10,939 $1.77 Million
Q1 2021

May 11, 2021

SELL
$102.3 - $112.62 $122,657 - $135,031
-1,199 Reduced 9.83%
10,993 $1.19 Million
Q4 2020

Feb 10, 2021

BUY
$80.49 - $108.67 $50,708 - $68,462
630 Added 5.45%
12,192 $1.31 Million
Q3 2020

Nov 10, 2020

SELL
$85.91 - $100.83 $53,264 - $62,514
-620 Reduced 5.09%
11,562 $1.01 Million
Q2 2020

Aug 17, 2020

BUY
$73.37 - $98.18 $29,054 - $38,879
396 Added 3.36%
12,182 $1.2 Million
Q1 2020

May 15, 2020

BUY
$64.5 - $97.79 $216,333 - $327,987
3,354 Added 39.78%
11,786 $898,000
Q4 2019

Feb 14, 2020

BUY
$72.13 - $90.25 $608,200 - $760,988
8,432 New
8,432 $747,000
Q3 2019

Nov 14, 2019

SELL
$62.98 - $75.72 $498,612 - $599,475
-7,917 Closed
0 $0
Q2 2019

Aug 15, 2019

BUY
$65.7 - $83.98 $104,660 - $133,780
1,593 Added 25.19%
7,917 $576,000
Q1 2019

May 16, 2019

BUY
$77.14 - $90.79 $487,833 - $574,155
6,324 New
6,324 $510,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $313B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Covenant Partners, LLC Portfolio

Follow Covenant Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Covenant Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Covenant Partners, LLC with notifications on news.